Systemic biomarkers of allogeneic haematopoietic stem cell transplantation outcome-Brief introduction
Jazyk angličtina Země Anglie, Velká Británie Médium print
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
Grantová podpora
IGA_LF_2019_014
Palacky University - International
MHCZ-DRO
University Hospital Olomouc - International
FNOl
University Hospital Olomouc - International
00098892
University Hospital Olomouc - International
PubMed
31729192
DOI
10.1111/tan.13761
Knihovny.cz E-zdroje
- Klíčová slova
- allograft/allogeneic transplantation, biomarkers, graft versus host disease, immune response,
- MeSH
- biologické markery krev MeSH
- hematologické nádory krev diagnóza terapie MeSH
- homologní transplantace škodlivé účinky MeSH
- lidé MeSH
- nemoc štěpu proti hostiteli krev diagnóza MeSH
- prediktivní hodnota testů MeSH
- prognóza MeSH
- transplantace hematopoetických kmenových buněk * škodlivé účinky MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Názvy látek
- biologické markery MeSH
Although complex approaches in haematopoietic stem cell transplantation (aHSCT) improved substantially in the last decades, considerable proportion of patients still suffer from life-threatening complications including graft versus host disease (GvHD). Great effort has therefore been dedicated to identification of biomarkers of the aHSCT outcome. Recently, prognostic scores for the prediction of GvHD and non-relapse mortality based on circulating molecules, such as tumour necrosis factor receptor-1, IL-33receptor (ST2) and regenerating islet-derived 3-alpha were proposed and evaluated in multicentre studies. Furthermore, several biomarkers, for example, ST2, represent promising targets for therapeutic intervention in severe GvHD. These results bring us closer to the clinical strategies to effectively control complications following aHSCT, and therefore to the tailored stem cell therapy with higher benefits for the patients.
Zobrazit více v PubMed
Petersdorf EW. Optimal HLA matching in hematopoietic cell transplantation. Curr Opin Immunol. 2008;20:588-593.
Morishima Y, Kashiwase K, Matsuo K, et al. Biological significance of HLA locus matching in unrelated donor bone marrow transplantation. Blood. 2015;125:1189-1197.
Fleischhauer K, Shaw BE, Gooley T, et al. Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncol. 2012;13:366-374.
Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010;116:2411-2419.
Bogunia-Kubik K, Lacina P. From genetic single candidate gene studies to complex genomics of GvHD. Br J Haematol. 2017;178:661-675.
Dickinson AM, Norden J. Non-HLA genomics: does it have a role in predicting haematopoietic stem cell transplantation outcome? Int J Immunogenet. 2015;42:229-238.
Radojcic V, Luznik L. PTCY keeps on giving! Blood. 2019;134:848-849.
Robinson TM, O'Donnell PV, Fuchs EJ, Luznik L. Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. Semin Hematol. 2016;53:90-97.
Levine JE, Braun TM, Harris AC, et al. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol. 2015;2:e21-e29.
Paczesny S, Metzger J. Clinical proteomics for post-hematopoeitic stem cell transplantation outcomes. Proteomics Clin Appl. 2019;13:e1800145.
Mrazek F, Schneiderova P, Kriegova E, et al. Profile of inflammation-associated proteins in early post-transplant samples of patients after allogeneic hematopoietic stem cell transplantation: a preliminary study. Arch Immunol Ther Exp (Warsz). 2016;64:55-61.
Hori T, Naishiro Y, Sohma H, et al. CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease. Blood. 2008;111:4403-4412.
Paczesny S, Krijanovski OI, Braun TM, et al. A biomarker panel for acute graft-versus-host disease. Blood. 2009;113:273-278.
Socié G. Graft-versus-host disease: proteomics comes of age. Blood. 2009;113:271-272.
McDonald GB, Tabellini L, Storer BE, Lawler RL, Martin PJ, Hansen JA. Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment. Blood. 2015;126:113-120.
Tvedt THA, Ersvaer E, Tveita AA, Bruserud Ø. Interleukin-6 in allogeneic stem cell transplantation: its possible importance for immunoregulation and as a therapeutic target. Front Immunol. 2017;8:667.
Major-Monfried H, Renteria AS, Pawarode A, et al. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood. 2018;131:2846-2855.
Ferrara JL, Harris AC, Greenson JK, et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011;118:6702-6708.
Hansen JA, Hanash SM, Tabellini L, et al. A novel soluble form of Tim-3 associated with severe graft-versus-host disease. Biol Blood Marrow Transplant. 2013;19:1323-1330.
Harris AC, Ferrara JL, Braun TM, et al. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood. 2012;119:2960-2963.
Paczesny S, Braun TM, Levine JE, et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med. 2010;2:13ra2.
Magenau JM, Qin X, Tawara I, et al. Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol Blood Marrow Transplant. 2010;16:907-914.
Peccatori J, Forcina A, Clerici D, et al. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia. 2015;29:396-405.
Loschi M, Porcher R, Peffault de Latour R, et al. High number of memory T cells is associated with higher risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21:569-574.
Hatano R, Ohnuma K, Yamamoto J, Dang NH, Yamada T, Morimoto C. Prevention of acute graft-versus-host disease by humanized anti-CD26 monoclonal antibody. Br J Haematol. 2013;162:263-277.
Huenecke S, Cappel C, Esser R, et al. Development of three different NK cell subpopulations during immune reconstitution after Pediatric allogeneic hematopoietic stem cell transplantation: prognostic markers in GvHD and viral infections. Front Immunol. 2017;8:109.
Battipaglia G, Malard F, Rubio MT, et al. Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria. Haematologica. 2019;104:1682-1688.
Andermann TM, Peled JU, Ho C, et al. The microbiome and hematopoietic cell transplantation: past, present and future. Biol Blood Marrow Transplant. 2018;24:1322-1340.
Vander Lugt MT, Braun TM, Hanash S, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med. 2013;369:529-539.
Ramadan AM, Daguindau E, Rech JC, et al. From proteomics to discovery of first-in-class ST2 inhibitors active in vivo. JCI Insight. 2018;3:99208.
Zhang J, Ramadan AM, Griesenauer B, et al. ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease. Sci Transl Med. 2015;7:308ra160.
Ohnuma K, Hatano R, Aune TM, et al. Regulation of pulmonary graft-versus-host disease by IL-26+CD26+CD4 T lymphocytes. J Immunol. 2015;194:3697-3712.
